Abstract: Claimed herein is a method of applying amorphous Co—SiOx to activate PMS and produce SO4·? due to the formation of Co(II)-Ov, pairs via the substitution of Si by Co. The inherent Co significantly change the electronic structure of O and Si atoms in the Co—SiOx via final state effects and increase the conductivity in terms of more effective electron transfers. The claimed method using Co—SiOx functions as a more effective oxidative catalyst for the faster degradation of pollutants. The simplicity of the synthetic procedures indicates that the conductive Co—SiOx could be used for the activation of PMS and other electrochemical applications on a wider scale.

Abstract: Claimed herein is a method of applying amorphous Co—SiOx to activate PMS and produce SO4.? due to the formation of Co(II)-Ov, pairs via the substitution of Si by Co. The inherent Co significantly change the electronic structure of O and Si atoms in the Co—SiOx via final state effects and increase the conductivity in terms of more effective electron transfers. The claimed method using Co—SiOx functions as a more effective oxidative catalyst for the faster degradation of pollutants. The simplicity of the synthetic procedures indicates that the conductive Co—SiOx could be used for the activation of PMS and other electrochemical applications on a wider scale.

Abstract: This invention is a novel method of manufacture for hand-sanitizing lotions that retains the added benefits of prolonged effectiveness while avoiding demulsification as well as the resulting product. The invention presents a novel, more simplified process comprising a lower cooking temperature and an optimized ingredient addition protocol, designed for product stability and ingredient integrity.

Abstract: This invention is a novel method of manufacture for hand-sanitizing lotions that retains the added benefits of prolonged effectiveness while avoiding demulsification as well as the resulting product. The invention presents a novel, more simplified process comprising a lower cooking temperature and an optimized ingredient addition protocol, designed for product stability and ingredient integrity.

Abstract: The invention relates to processes for producing an immunoglobulin or an immunologically functional immunoglobulin fragment containing at least the variable domains of the immunoglobulin heavy and light chains. The processes can use one or more vectors which produce both the heavy and light chains or fragments thereof in a single cell. The invention also relates to the vectors used to produce the immunoglobulin or fragment, and to cells transformed with the vectors.

Abstract: Novel 2 polypeptides with binding affinity for the p185HER2 receptor, designated heregulin 2-? and heregulin 2-?, have been identified and purified from human tissue. The cDNA encoding the novel heregulin 2-? has been isolated from human tissue and sequenced. Provided herein is nucleic acid sequence of the heregulin 2-? useful in the production of heregulin 2-? by recombinant means. Further provided an amino acid sequence of heregulin 2-? and heregulin 2-?. Heregulins and their antibodies are useful as therapeutic agents and in diagnostic methods.

Abstract: Novel 2 polypeptides with binding affinity for the p185HER2 receptor, designated heregulin 2-? and heregulin 2-?, have been identified and purified from human tissue. The cDNA encoding the novel heregulin 2-? has been isolated from human tissue and sequenced. Provided herein is nucleic acid sequence of the heregulin 2-? useful in the production of heregulin 2-? by recombinant means. Further provided an amino acid sequence of heregulin 2-? and heregulin 2-?. Heregulins and their antibodies are useful as therapeutic agents and in diagnostic methods.

Abstract: Novel 2 polypeptides with binding affinity for the p185HER2 receptor, designated heregulin 2-&agr; and heregulin 2-&bgr;, have been identified and purified from human tissue. The cDNA encoding the novel heregulin 2-&agr; has been isolated from human tissue and sequenced. Provided herein is nucleic acid sequence of the heregulin 2-&agr; useful in the production of heregulin 2-&agr; by recombinant means. Further provided an amino acid sequence of heregulin 2-&agr; and heregulin 2-&bgr;. Heregulins and their antibodies are useful as therapeutic agents and in diagnostic methods.

Abstract: Novel polypeptides with binding affinity for the p185HER2 receptor, designated heregulin 2-&agr; and heregulin 2-&bgr;, have been identified and purified from human tissue. The cDNA encoding the novel heregulin 2-&agr; has been isolated from human tissue and sequenced. Provided herein is nucleic acid sequence of the heregulin 2-&agr; useful in the production of heregulin 2-&agr; by recombinant means. Further provided an amino acid sequence of heregulin 2-&agr; and heregulin 2-&bgr;. Heregulins and their antibodies are useful as therapeutic agents and in diagnostic methods.

Abstract: The invention relates to processes for producing an immunoglobulin or an immunologically functional immunoglobulin fragment containing at least the variable domains of the immunoglobulin heavy and light chains. The processes can use one or more vectors which produce both the heavy and light chains or fragments thereof in a single cell. The invention also relates to the vectors used to produce the immunoglobulin or fragment, and to cells transformed with the vectors.

Abstract: Novel polypeptides with binding affinity for the p185.sup.HER2 receptor, designated heregulin 2-.alpha. and heregulin 2-.beta., have been identified and purified from human tissue. The cDNA encoding the novel heregulin 2-.alpha. has been isolated from human tissue and sequenced. Provided herein is nucleic acid sequence of the heregulin 2-.alpha. useful in the production of heregulin 2-.alpha. by recombinant means. Further provided an amino acid sequence of heregulin 2-.alpha. and heregulin 2-.beta.. Heregulins and their antibodies are useful as therapeutic agents and in diagnostic methods.

Abstract: The cDNA encoding a member of or a class of novel PF4A receptors has been identified in human tissue. Provided herein is nucleic acid sequence of a PF4A receptor (the IL-8 receptor) useful as a diagnostic and in the recombinant preparation of PF4A receptors. The PF4A receptor is used in the preparation and purification of antibodies capable of binding to the receptor, and in diagnostic assays.

Abstract: Novel 2 polypeptides with binding affinity for the p185.sup.HER2 receptor, designated heregulin 2-.alpha. and heregulin 2-.beta., have been identified and purified from human tissue. The cDNA encoding the novel heregulin 2-.alpha. has been isolated from human tissue and sequenced. Provided herein is nucleic acid sequence of the heregulin 2-.alpha. useful in the production of heregulin 2-.alpha. by recombinant means. Further provided an amino acid sequence of heregulin 2-.alpha. and heregulin 2-.beta.. Heregulins and their antibodies are useful as therapeutic agents and in diagnostic methods.

Abstract: A novel polypeptide with binding affinity for the p185.sup.HER2 receptor, designated heregulin-.alpha., has been identified and purified from cultured human cells. DNA sequences encoding additional heregulin polypeptides, designated heregulin-.alpha., heregulin-.beta.1, heregulin-.beta.2, heregulin-.beta.2-like, and heregulin-.beta.3, have been isolated, sequenced and expressed. Provided herein are nucleic acid sequences encoding the amino acid sequences of heregulins useful in the production of heregulins by recombinant means. Further provided are the amino acid sequences of heregulins and purification methods therefor. Heregulins and their antibodies are useful as therapeutic agents and in diagnostic methods.

Abstract: Novel 2 polypeptides with binding affinity for the p185.sup.HER2 receptor, designated heregulin 2-.alpha. and heregulin 2-.beta., have been identified and purified from human tissue. The cDNA encoding the novel heregulin 2-.alpha. has been isolated from human tissue and sequenced. Provided herein is nucleic acid sequence of the heregulin 2-.alpha. useful in the production of heregulin 2-.alpha. by recombinant means. Further provided an amino acid sequence of heregulin 2-.alpha. and heregulin 2-.beta.. Heregulins and their antibodies are useful as therapeutic agents and in diagnostic methods.

Abstract: The cDNA encoding a member of or a class of novel PF4A receptors has been identified in human tissue. Provided herein is nucleic acid sequence of a PF4A receptor (the IL-8 receptor) useful as a diagnostic and in the recombinant preparation of PF4A receptors. The PF4A receptor is used in the preparation and purification of antibodies capable of binding to the receptor, and in diagnostic assays.

Abstract: The cDNA encoding a member of or a class of novel PF4A receptors has been identified in human tissue. Provided herein is nucleic acid sequence of a PF4A receptor (the IL-8 receptor) useful as a diagnostic and in the recombinant preparation of PF4A receptors. The PF4A receptor is used in the preparation and purification of antibodies capable of binding to the receptor, and in diagnostic assays.

Abstract: A novel polypeptide with binding affinity for the p185.sup.HER2 receptor, designated heregulin-.alpha., has been identified and purified from cultured human cells. DNA sequences encoding additional heregulin polypeptides, designated heregulin-.alpha., heregulin-.beta.1, heregulin-.beta.2, heregulin-.beta.2-like, and heregulin-.beta.3, have been isolated, sequenced and expressed. Provided herein are nucleic acid sequences encoding the amino acid sequences of heregulins useful in the production of heregulins by recombinant means. Further provided are the amino acid sequences of heregulins and purification methods therefor. Heregulins and their antibodies are useful as therapeutic agents and in diagnostic methods.

Abstract: The cDNA encoding a member of or a class of novel PF4A receptors has been identified in human tissue. Provided herein is nucleic acid sequence of a PF4A receptor (the IL-8 receptor) useful as a diagnostic and in the recombinant preparation of PF4A receptors. The PF4A receptor is used in the preparation and purification of antibodies capable of binding to the receptor, and in diagnostic assays.

Abstract: The cDNA encoding a member of or a class of novel PF4A receptors has been identified in human tissue. Provided herein is nucleic acid sequence of a PF4A receptor (the IL-8 receptor) useful as a diagnostic and in the recombinant preparation of PF4A receptors. The PF4A receptor is used in the preparation and purification of antibodies capable of binding to the receptor, and in diagnostic assays.